KHN705

KHN705 is a biosynthetically derived natural product small molecule being developed by Chengdu Kanghong Pharmaceutical for the treatment of various solid and hematological malignancies. It is designed to target tumor metabolic reprogramming, a strategy also employed by the company's Phase II candidate KH617. KHN705 has demonstrated broad-spectrum anti-tumor activity in preclinical models, showing efficacy comparable to standard chemotherapy in gastric, hepatocellular, lung, and brain cancers. Notably, it maintains activity in cisplatin- and 5-fluorouracil-resistant cell lines. The compound is characterized by a favorable safety profile, significant oral bioavailability, and a prolonged half-life, with a unique pharmacokinetic profile that shows preferential accumulation in gastric tissue, suggesting particular potential for the treatment of gastric cancer.